Tirtha Pandya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tirtha Pandya has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
A. Feroz
Department of Nephrology and Transplantation Medicine, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases and Research Centre and Dr H.L. Trivedi Institute of Transplantation Sciences, Ahmedabad, Gujarat, India
1 shared publicationA.V. Vanikar
Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases and Research Centre and Dr H.L. Trivedi Institute of Transplantation Sciences, Ahmedabad, Gujarat, India
1 shared publicationD. Saboo
Department of Nephrology and Transplantation Medicine, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases and Research Centre and Dr H.L. Trivedi Institute of Transplantation Sciences, Ahmedabad, Gujarat, India
1 shared publication- Dona Susan Mathew
Department of Microbiology, Amrita Institute of Medical Science and Research Centre, Amrita Vishwa Vidyapeetham, Kochi 608204, India
1 shared publication - Hargovind L. Trivedi
Department of Nephrology and Transplantation Medicine, Institute of Kidney Diseases and Research Centre (IKDRC)-Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS), Ahmedabad, Gujarat, India
1 shared publication - Het Pandya
Public Health Research Institute (PHRI) Center, New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA
1 shared publication
Latest Publications
- Open Access
- 24 October 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (11) , 1565
An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines
The Coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has significantly impacted the health and socioeconomic status of humans worldwide. Pulmonary infection of SARS-CoV-2 results in exorbitant viral replication and associated onset of inflammatory cytokine storm and disease pathology in various internal organs. However, the etiopathogenesis of SARS-CoV-2 infection is not fully understood. Currently, there are no targeted therapies available to cure COVID-19, and most patients are treated empirically with anti-inflammatory and/or anti-viral drugs, based on the disease symptoms. Although several types of vaccines are currently implemented to control COVID-19 and prevent viral dissemination, the emergence of new variants of SARS-CoV-2 that can evade the vaccine-induced protective immunity poses challenges to current vaccination strategies and highlights the necessity to develop better and improved vaccines. In this review, we summarize the etiopathogenesis of SARS-CoV-2 and elaborately discuss various types of vaccines and vaccination strategies, focusing on those vaccines that are currently in use worldwide to combat COVID-19 or in various stages of clinical development to use in humans.
- 24 October 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (11) , 1565
Open AccessAn Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines
The Coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has significantly impacted the health and socioeconomic status of humans worldwide. Pulmonary infection of SARS-CoV-2 results in exorbitant viral replication and associated onset of inflammatory cytokine storm and disease pathology in various internal organs. However, the etiopathogenesis of SARS-CoV-2 infection is not fully understood. Currently, there are no targeted therapies available to cure COVID-19, and most patients are treated empirically with anti-inflammatory and/or anti-viral drugs, based on the disease symptoms. Although several types of vaccines are currently implemented to control COVID-19 and prevent viral dissemination, the emergence of new variants of SARS-CoV-2 that can evade the vaccine-induced protective immunity poses challenges to current vaccination strategies and highlights the necessity to develop better and improved vaccines. In this review, we summarize the etiopathogenesis of SARS-CoV-2 and elaborately discuss various types of vaccines and vaccination strategies, focusing on those vaccines that are currently in use worldwide to combat COVID-19 or in various stages of clinical development to use in humans.
- 1 May 2008
- Published by Elsevier in Transplantation Proceedings
- Vol. 40 (4) , 1114-1116
Postrenal Transplant Hemolytic Uremic Syndrome/Thrombotic Microangiopathy: Ahmedabad Experience
- 1 May 2008
- Published by Elsevier in Transplantation Proceedings
- Vol. 40 (4) , 1114-1116
Postrenal Transplant Hemolytic Uremic Syndrome/Thrombotic Microangiopathy: Ahmedabad Experience